Bacoside-A from Bacopa monnieri (L.) Wettst. in Parkinson's disease: In Silico and preclinical insights into dopaminergic neuroprotection.
Bacoside-A from Bacopa monnieri (L.) Wettst. in Parkinson's disease: In Silico and preclinical insights into dopaminergic neuroprotection.
A plain-language reading has not been prepared for this paper yet.
Original abstract
Parkinson's disease (PD) presents a formidable therapeutic challenge rooted not in a singular pathogenic event but in the convergent failure of mitochondrial homeostasis, redox balance, α-synuclein proteostasis, autophagy-lysosomal integrity, and neuroinflammatory amplification within substantia nigra dopaminergic neurons. Existing dopaminergic pharmacotherapies address symptomatic deficits while leaving the underlying neurodegenerative cascade unchecked, underscoring the need for disease-modifying strategies with multi-target mechanistic reach. This review examines bacoside-A, the principal triterpenoid saponin complex of Bacopa monnieri (L.) Wettst., as a structurally distinctive, polypharmacological neuroprotective scaffold whose biological relevance emerges from convergence with core vulnerability pathways driving dopaminergic degeneration. Integrating in silico, in vitro, and in vivo evidence, we examine how bacoside-A engages molecular targets including α-synuclein aggregation intermediates, monoamine oxidase-B, LRRK2 kinase, PINK1-Parkin mitophagy regulators, and the redox sensor DJ-1, with computational predictions providing a coherent mechanistic framework for findings observed across MPP⁺-, rotenone-, and 6-OHDA-based preclinical models, including attenuation of mitochondrial dysfunction, oxidative amplification, and apoptotic signalling, and partial nigrostriatal preservation with motor improvement in vivo. This review reframes bacoside-A as a stress-buffering, network-active modulator most relevant during early, pre-degenerative disease stages. While no clinical trial has yet evaluated bacoside-A in PD, and findings from cognitive or other non-PD indications cannot be extrapolated as efficacy evidence, the convergent mechanistic, computational, and preclinical evidence presented here provides a strong rationale for advancing bacoside-A toward systems pharmacology-guided preclinical and clinical evaluation as an adjunct neuroprotective candidate.